Project Grant R41CA195926

This $546,625 Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) is focused on developing a novel immunochemotherapy approach for treating metastatic colorectal cancer (mCRC). The key products and services to be delivered under this 5-year award (1/9/2025 - 12/31/2029) include: Developing and characterizing a nanocarrier platform (PCL-CP) capable of co-delivering siRNA targeting the IRHOM1 gene and a prodrug conjugate of camptothecin...

This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $798,512 to Luminary Therapeutics, Inc. to develop an innovative allogeneic gamma/delta CAR T-cell therapy targeting epithelial ovarian carcinoma. The key products and services to be delivered under this award include: Engineering an "armored split CAR" that combines two CAR molecules targeting different antigens (mesothelin and chondroitin sulfate proteoglycan-4) on a...

The National Cancer Institute (NCI), through its Cancer Treatment Research program (CFDA 93.395), has awarded a $402,402 R21 project grant to the University of Louisville's Office of Research & Innovation. The goal of this 2-year grant, which began on September 19, 2023, is to develop and evaluate a novel tumor glycobiomarker-targeting agent called AVFC Lectibody as a potential immunotherapeutic and diagnostic agent against non-small cell lung cancer (NSCLC). The research aims to assess...

This $1,013,623 Project Grant awarded by the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) to March Biosciences Inc. aims to develop dual-targeting chimeric antigen receptor (CAR) T-cell therapies for the treatment of T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoma (TCL). The grant will fund the development of CD5/CD7.CAR-T cells derived from haploidentical, CD45RA-depleted donor T-cells (RAD-T) to target malignant T-cells with varying antigen expression....

This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $1,418,424 to Tigatx Inc., a small business located in Boston, MA, to support the late-stage development and de-risking of a novel monoclonal antibody immunotherapy called TIGA-001 for EGFR-positive solid cancers, with a focus on non-small cell lung cancer (NSCLC). The award will fund activities to progress TIGA-001 into clinical testing, including chemistry, manufacturing, and controls...

The Project Grant award R01CA287491, totaling $720,416, was provided by the National Cancer Institute (NCI) under the federal Cancer Detection and Diagnosis Research program (CFDA 93.394). The award aims to develop a novel "theranostic" (therapeutic and diagnostic) approach using chimeric antigen receptor (CAR) T-cell therapy for the treatment of neuroendocrine prostate cancer (NEPC). The key products and services to be delivered include: Evaluating the therapeutic efficacy of...

This $1,398,552 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports Avantgen Inc., a San Diego-based biotechnology company, in conducting preliminary IND-enabling studies for a novel antibody therapy targeting the Jagged-1 pathway in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). The key products and services to be delivered under this grant include cell line development, early chemistry and manufacturing controls (CMC)...

The National Cancer Institute awarded a $400,000.00 Project Grant (CFDA 93.395 - Cancer Treatment Research) to Nuago Therapeutics Inc., a self-certified small disadvantaged business located in Chicago, IL. The 1-year grant, awarded on June 9, 2025, will support the development of a DISE-inducing, short RNA therapeutic to treat ovarian cancer. The project aims to advance innovative cancer treatment approaches beyond existing targeted therapies and checkpoint inhibitor immunotherapies, which...

This Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) is focused on developing a "next-generation" precision adoptive T cell therapy approach to treat pediatric high-grade gliomas. The $474,656 award will fund research to evaluate the safety, efficacy, and immunological effects of this therapy in preclinical models, determine the capacity to isolate and expand antigen-specific T cells from pediatric patients, and conduct a Phase 1...

The National Cancer Institute (NCI) has awarded a $435,773 Project Grant (CFDA 93.395 - Cancer Treatment Research) to the University of Maryland, Baltimore (UMB) to develop an engineered prodrug capable of selectively delivering potent cytotoxins to malignant tumor cells. The goal is to leverage hyperactive membrane-anchored serine proteases (MASPs) on the surface of tumor cells to activate the prodrug and selectively kill cancer cells, particularly in ovarian, lung, and colon cancers. The...